Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate‐pair sequencing
暂无分享,去创建一个
Sarah H. Johnson | G. Vasmatzis | A. Tefferi | T. Lasho | A. Pardanani | J. Crispino | David I. Smith
[1] M. Cazzola,et al. Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.
[2] R. Laborde,et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML , 2013, Leukemia.
[3] A. Tefferi,et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. , 2012, Blood.
[4] David I. Smith,et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. , 2012, Blood.
[5] A. Tefferi,et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients , 2012, Leukemia.
[6] Bodo Grimbacher,et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. , 2012, American journal of human genetics.
[7] A. Tefferi,et al. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management , 2012, American journal of hematology.
[8] A. Tefferi,et al. TP53 mutations and polymorphisms in primary myelofibrosis , 2011, American journal of hematology.
[9] A. Tefferi,et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F , 2011, Leukemia.
[10] A. Tefferi. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management , 2011, American journal of hematology.
[11] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[12] A. Tefferi,et al. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post‐polycythemia vera myelofibrosis , 2011, American journal of hematology.
[13] A. Tefferi. Mutations galore in myeloproliferative neoplasms: Would the real Spartacus please stand up? , 2011, Leukemia.
[14] O. Abdel-Wahab,et al. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms , 2011, Leukemia.
[15] F. Passamonti,et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] John M Denu,et al. Identification of Macrodomain Proteins as Novel O-Acetyl-ADP-ribose Deacetylases* , 2011, The Journal of Biological Chemistry.
[17] David I. Smith,et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. , 2011, Blood.
[18] D. Gilliland,et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms , 2010, Leukemia.
[19] A. Tefferi,et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients , 2010, Leukemia.
[20] X. Guan,et al. Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma , 2010, Acta Pharmacologica Sinica.
[21] A. Tefferi,et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations , 2010, Leukemia.
[22] M. Cazzola,et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms , 2010, Leukemia.
[23] A. Tefferi,et al. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 , 2010, Leukemia.
[24] O. Abdel-Wahab,et al. Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms , 2009, American journal of hematology.
[25] J. Soulier,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[26] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[27] R. Mesa,et al. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis , 2009, European journal of haematology.
[28] D. Gilliland,et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.
[29] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.
[30] A. Hall,et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. , 2008, Blood.
[31] Eric W. Klee,et al. Quantitating tissue specificity of human genes to facilitate biomarker discovery , 2007, Bioinform..
[32] J. Weber,et al. A 360-kb interchromosomal duplication of the human HYDIN locus. , 2006, Genomics.
[33] J. Reilly,et al. Der(6)t(1;6)(q21–23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia , 2005, British journal of haematology.
[34] Han Liu,et al. Functional contribution of EEN to leukemogenic transformation by MLL-EEN fusion protein , 2004, Oncogene.
[35] Chi Wai So,et al. Identification and characterization of EBP, a novel EEN binding protein that inhibits Ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein. , 2004, Blood.
[36] B. Druker,et al. Perspectives on the development of a molecularly targeted agent. , 2002, Cancer cell.